January 2022 in “Journal of family medicine” This case report highlights the challenges of misdiagnosis in women with PCOS and emphasizes the importance of a holistic approach to address interconnected endocrine and reproductive dysfunctions.
November 2025 in “Frontiers in Endocrinology” This review examines the potential of apigenin and ellagic acid as adjunct or alternative treatments for PCOS, but reports no new clinical results and highlights the need for further trials to confirm their efficacy and optimize dosing and delivery.
February 2026 in “International Journal on Science and Technology” This review discusses the potential benefits of Vitex negundo for managing polycystic ovarian disease, highlighting its promising effects in animal models, but notes that more rigorous human trials are needed to confirm these findings.
This review examines the potential of Parquetina nigrescens for managing Polyendocrine Metabolic Ovarian Syndrome, emphasizing its pharmacological activities and highlighting its promise as an affordable complementary therapy.
1 citations
,
October 2023 in “Egyptian Journal of Immunology” This study found that women with PCOS had significantly higher levels of the pro-inflammatory chemokine MIP-1α compared to controls, suggesting an association with low-grade chronic inflammation, though the increase in MIP-1β levels did not reach statistical significance.
